首页> Cancer immunology, immunotherapy :> A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

导出原文传递

翻译打印收藏纠错

第一作者： Meckler, Joshua F.

作者： Meckler, Joshua F. ^[1] ; Levis, Daniel J. ; Vang, Daniel P. ; Tuscano, Joseph M.

作者单位： University of California System,Univ Calif Davis ^[1]

关键词 Bispecific T-cell engager CD22 CD3 Acute lymphoblastic leukemia (ALL)SINGLE-CHAIN ANTIBODY CD19 X CD3 LYMPHOMA XENOGRAFTS RESISTANCE ADHESION RECEPTOR

发布时间 2023-10-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer immunology, immunotherapy

2023年72卷9期

2939-2948页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer immunology, immunotherapy

2023年72卷9期

2939-2948页

检索历史清除

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Cancer immunology, immunotherapy

相似文献

同项目论文

Cancer immunology, immunotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Cancer immunology, immunotherapy

相似文献

同项目论文

Cancer immunology, immunotherapy

相关期刊

检索历史清除